PMC4246688_01
Hematoxylin and eosin-stained section revealing small cell cervical carcinoma with hyperchromatic nuclei and scant cytoplasm (magnification, x100).
OL-09-01-0091-g00.jpg
PMC4246688_01_OL-09-01-0091-g00.jpg
f1-ol-09-01-0091
On histological examination, the mass was diagnosed as SCCC (Fig 1). Based on the histological and radiographical observations (Fig. 1), the tumor was diagnosed as SCCC, and classified as International Federation of Gynecology and Obstetrics (FIGO) stage IB2.
MRI of the pelvis. (A) Prior to treatment, MRI identified an ~6.0x6.0-cm cervical carcinoma, and invasion of the posterior wall of vagina and pelvic lymph nodes. (B) Following two cycles of NACT for six weeks, a decrease in the volume of the vaginal mass was observed. (C) Following four cycles of NACT for 12 weeks, complete clinical remission was achieved. (a) transverse section and (b) median sagittal section. MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy.
OL-09-01-0091-g03.jpg
PMC4246688_01_OL-09-01-0091-g03.jpg
f2-ol-09-01-0091
Magnetic resonance imaging (MRI) confirmed a 5.8x5.7-cm cervical carcinoma and swelling of the lymph nodes in the pelvis (Fig. 2). After the fourth cycle of NACT, MRI revealed a 90% decrease in tumor size when compared with previous MRI scans of the cervical mass and an 80% decrease in size of the lymph nodes (Fig. 2).